阅读并同意隐私协议、MTA和使用条款后进行下一步!
Across the global bio-manufacturing industry, theoretical breakthroughs are everywhere, while mass-production breakthroughs that truly reach industrial implementation are extremely rare.
Cell-free protein synthesis (CFPS) is a frontier technology track that the world has developed for more than seventy years. It abandons the conventional cell-culture model and directly uses ribosomes, translation factors, aminoacyl-tRNA synthetases and amino acids to complete transcription and translation independently in vitro, compressing a protein preparation cycle that traditionally takes days down to a few hours.
For years, the whole world has been stuck at the same ultimate bottleneck: it can do experiments, but not mass production; it can do micro amounts, but cannot scale up. Once the reaction volume is raised, a series of problems erupt together — imbalanced mass transfer, insufficient energy supply, declining quality, rising costs and product inhibition — leaving global CFPS trapped for a long time in laboratory microplate systems, with reaction volumes mostly remaining at the microliter and milliliter level and never entering the industrialization era.
It is Healthcode that put a definitive end to this global technological deadlock!
Technical feasibility is only the starting point; reproducible processes, supporting equipment and scalable production are the ultimate core of bio-manufacturing.
Building on a solid hundred-ton-scale raw material capacity base, Healthcode achieved another world-class breakthrough in 2024: it released the world's first cell-free protein synthesis large-scale industrial reactor, and has now completed the development of a series of large-scale CFPS Bio-Reactor products — 100L, 1000L and 10000L — taking the lead in achieving a leap from hundred-ton-scale raw material supply to thousand-liter and ten-thousand-liter in vitro batch synthesis. It has become the physical cornerstone supporting downstream applications of cell-free protein synthesis industrialization, setting another world first, completing the full-chain industrialization loop of cell-free synthesis, and is rightly called the “next-generation lithography machine” of the biopharmaceutical field!
On the basis of scaled manufacturing, Healthcode pays even more attention to supporting the development of basic scientific research. To help research laboratories and R&D institutions better use cell-free protein synthesis technology and scale-up R&D, it spent three years developing the liter-scale cell-free in vitro synthesis bioreactor, CFPS Bio-Reactor S200.
CFPS Bio-Reactor S200 goes beyond the traditional limits of “microliter” and “milliliter” and “ng, microgram” cell-free in vitro synthesis reaction volumes, taking laboratory cell-free in vitro synthesis completely out of the “microplate” system that could only be used for small-scale testing, leaping to the “liter” level and the milligram-to-gram preparation level, empowering efficient manufacturing, analysis, functional and structural characterization, cell and animal experiments and preclinical research of various highly active proteins for scientific R&D.
The newly launched CFPS Bio-Reactor S200 is the first intelligent cell-free protein synthesis reactor spanning small, medium and large volumes, carrying the mission of China's hard-core bio-manufacturing breakthrough: equipped with 6 independent reaction vessels and up to 24 independent reaction channels, with 10–200 mL flexible adjustment per channel and a maximum reaction volume of 1200 mL; paired with ProteinFactory Liter-grade Healthcode protein factory synthesis reagents — eukaryotic cell-free, higher activity, better folding, compatible with more complex protein sequences — and a system expansion unit module that can break through and upgrade the system; maximum output of 2.4 g of active protein per batch, with ultra-fast synthesis in 0.5–3 hours!
CFPS Bio-Reactor S200 offers full-process AI intelligent regulation, full-data digital traceability, remote unattended operation and 100% pure Chinese intelligent manufacturing.
The epoch-making value of CFPS Bio-Reactor S200 goes far beyond the instrument parameters themselves! It has completely rewritten the research paradigm of global CFPS basic research: upgrading inefficient, small-scale, trial-and-error laboratory exploration into a parallel high-throughput, large-volume, characterizable, analyzable, scalable, iterable and generalizable industrial intelligent manufacturing system, turning research experience into national-level industrial technology assets that can be accumulated, passed on and developed.
The industry consensus is that whether a synthesis technology has truly landed depends on only three hard criteria: dedicated equipment, continuous scale-up and programmable processes. Today, cell-free synthesis has formally bid farewell to the laboratory trial-and-error era and entered a new stage of engineering, standardization and industrialization.
For a long time, limited by the manufacturing scale of cell-free synthesis raw materials and the lack of dedicated cell-free synthesis equipment, global cell-free synthesis research has relied on 96-well and 384-well microplate micro-reactions, able to perform only microliter- and milliliter-level micro-validation and hard-pressed to provide milligram- or gram-level target protein synthesis; yields are extremely low and costs extremely high, unable to support downstream functional and structural studies or other in-depth research including cell activity, animal experiments and preclinical development — let alone clinical research. There exists a technical gap of “micro-scale experiment — pilot scale-up” that cannot be crossed.
Based on its long-term technology accumulation in the industrialization of cell-free protein synthesis, its scaled manufacturing equipment and its rich experience in industrializing its own products, Healthcode used world-leading industrialization technology to feed back into upstream scientific research, and specially developed this CFPS Bio-Reactor S200 for laboratories and research institutions — an upgraded reactor, a desktop device, the world's first of its kind, a revolutionary instrument that truly bridges the gap from theory to manufacturing!
CFPS Bio-Reactor S200 is the first in the world to successfully upgrade the eukaryotic cell-free high-fidelity synthesis system from laboratory microliter microplate reactions to a “liter-scale”, scaled dedicated reaction device. It is the world's first dedicated upgraded cell-free synthesis instrument, stably achieving mass production of gram-level-and-above, highly folded, highly active, high-fidelity target proteins.
Connected with the Healthcode CFPS Bio-Reactor 10L, 100L, 1000L and 10000L large-scale reaction equipment already released for mass production, CFPS Bio-Reactor S200 completes the milliliter-to-liter reaction scale, allowing scientists to carry out scaled protein synthesis directly in the laboratory. At this point, relying on the world's first hardware architecture, AI intelligent coupling algorithms and a fully independent domestic equipment system, Healthcode has completely opened up the full industrialization blueprint from micro-scale research, liter-scale pilot scale-up and kilogram-scale amplification to ten-thousand-ton-scale mass production!
At this moment, Healthcode has once again established its absolute leadership, technology-defining position and industry-leading position in the global cell-free protein synthesis industry!
It not only builds a hard-core, independently controllable foundation for China's next-generation biopharmaceuticals, green bio-manufacturing, food security and national health, but also provides disruptive hardware support and an industrialization landing platform for AI protein design and global innovation in synthetic biology!
Disrupting the era, leading domestically! Chinese intelligent manufacturing, leading the world!